No, the title does not refer to sex, a Ferrari, a promotion, or winning the lottery. It’s a quote from Dr. Robert Nam from Toronto’s Sunnybrook Health Sciences Centre about the number of applicants for a clinical study of using 3T MRI to screen for prostate cancer (PCa).[i] There were 50 openings, but 300 applicants. keep reading
A newly available prostate cancer treatment has made Kaiser Permanente, one of the largest not-for-profit health plans, sit up and take notice. On October 4, 2016, the life sciences news service StatNews featured an article by Kaiser News staffer Julie Appleby, “Billboards and Websites Push Costly Prostate Cancer Treatment With Unknown Long-Term Benefits.”[i] The treatment keep reading
It’s time to silence the economic naysayers who claim that multiparametric MRI (mpMRI) is too expensive for detecting and diagnosing prostate cancer. Results from a new study out of Brigham and Women’s Hospital[i] (Boston, MA) in partnership with AdMeTech reflect how the Sperling Prostate Center has been ahead of its time. The study demonstrates how keep reading
The word is out: Patients with early stage, low risk prostate cancer have often been rushed into radical prostatectomy when many of them could have afforded to wait to seek treatment—possibly for years. Untold numbers of men were left with urinary and sexual problems that lasted for months, or were never fully resolved. For low keep reading
The fact that an opinion has been widely held is no evidence whatever that it is not utterly absurd. – Bertrand Russell What man over the age of, say, 45 doesn’t look back—perhaps nostalgically—on the lusty days of yore? Somewhere between the ages of eighteen to thirty, men reach a sexual peak in which desire keep reading
Androgen deprivation therapy (ADT) is a treatment for prostate cancer that has spread outside the gland. It is also called hormone therapy or chemical castration. The purpose of ADT is to reduce the production of male hormones, especially testosterone, which has the effect of temporarily halting the ability of prostate cancer cells to multiply and keep reading
Dr. Peter Pinto is one of the most respected urologic researchers in America. He is the Head of the Prostate Cancer Section of the Urologic Oncology Branch of the Center for Cancer Research (National Cancer Institute/National Institutes of Health). That’s a very long formal title for a man who is humble, personable and good-natured. His keep reading
Everyone knows that money doesn’t buy happiness. But can it buy life? A new study out of the University of Washington Medical Center suggests that prostate cancer patients in extreme financial distress are more likely to die than those who are not. This doesn’t mean that having money can buy life, but hardship is a keep reading
When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading
I never cease to be amazed at the amount of publication that comes from various individuals and teams at the University College London. On top of their clinical work with patients, and conducting clinical trials, I am impressed with their commitment and energy level when it comes to setting fingers to keyboard and writing articles keep reading